{"id":"W2135258573","doi":"10.1016/j.ctrv.2009.12.003","title":"Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and interpretation of clinical trial data","year":2010,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Canadian Centre for Applied Research in Cancer Control","keywords":"Medicine; Bevacizumab; Renal cell carcinoma; Oncology; Targeted therapy; Combination therapy; Internal medicine; Kidney cancer; Context (archaeology); Alpha interferon; Cancer; Chemotherapy; Immunology; Interferon","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008887157,0.001137278,0.009072165,0.0007514082,0.00005147167,0.00003749696,0.0003597004,0.0006043329,0.0001382871],"category_scores_gemma":[0.0001092752,0.0006992469,0.001952505,0.0008816832,0.0001390635,0.0002444493,0.0001185074,0.0004219189,0.00003200387],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001757408,"about_ca_system_score_gemma":0.001479335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001652239,"about_ca_topic_score_gemma":0.002201613,"domain_scores_codex":[0.9924528,0.001170811,0.003621379,0.001974915,0.0003630835,0.0004169967],"domain_scores_gemma":[0.9937976,0.0003212179,0.002286121,0.003049875,0.00009220366,0.0004529583],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.005331904,0.002276538,0.001104271,0.003847971,0.001206667,0.0001155169,0.0001562795,0.000002014401,0.000004032651,0.000002642624,0.000007149401,0.985945],"study_design_scores_gemma":[0.04917817,0.01553941,0.0008066319,0.006024896,0.08049524,0.00005376796,0.00002659122,0.0003632309,0.0000485665,0.000004305115,0.8468575,0.0006017291],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.05477367,0.9347695,0.00002130542,0.0000168586,0.0003275928,0.009312991,0.0004061003,0.00002266256,0.0003493367],"genre_scores_gemma":[0.006522716,0.9799685,0.001552292,0.00001500571,0.0004041677,0.00318437,0.007722929,0.00008117333,0.0005488389],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9853433,"threshold_uncertainty_score":0.9995459,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2358608435347219,"score_gpt":0.4972069989666378,"score_spread":0.2613461554319159,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}